Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Comparison Between U-100 Regular Human Insulin and Rapid Acting Insulin When Delivered by VGo Wearable Insulin Delivery in Type 2 Diabetes

NCT03495908 is registered in ClinicalTrials.gov with East Coast Institute for Research as lead sponsor.

NCT NCT03495908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03495908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Comparison Between U-100 Regular Human Insulin and Rapid Acting Insulin When Delivered by VGo Wearable Insulin Delivery in Type 2 Diabetes
Lead sponsor
East Coast Institute for Research
Phase
Not applicable
Overall status
Completed
Start date
April 9, 2018
Completion date
August 12, 2019
Enrollment
136 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes, type 2 diabetes mellitus